Paul M. Barr, MD, Examines Head-to-Head Data on BTK Inhibitors in Previously Treated, High-Risk CLL

News
Video

CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.

When asked about which research presentation from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting had the greatest potential to impact future treatment of chronic lymphocytic leukemia (CLL), Paul M. Barr, MD, of the University of Rochester Medical Center, talked about findings from a phase 3 trial comparing 2 Bruton tyrosine kinase inhibitors as treatment for patients with previously treated high-risk disease. These results are the first to compare these standard-of-care agents in a head-to-head, randomized fashion in this setting.

Transcript:

In terms of CLL, everyone is very much looking forward to seeing the granular data for the ELEVATE[-RR (NCT02477696)] study.2 This was a randomized study enrolling high-risk, relapse patients to single-agent ibrutinib [Imbruvica] or single-agent acalabrutinib [Tecentriq]. We saw press releases suggesting noninferiority for acalabrutinib compared with ibrutinib and perhaps a lower rate of arrhythmias and other cardiac events.2 What we know right now is that we have 2 really good single agents. We really need to look at the presentation and the specifics of the datasets to understand the subtle differences between the 2 agents. I think that’s one of many abstracts that everyone’s really looking forward to seeing a little more closely.

References

Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2021;39(suppl 15):7500. doi:10.1200/JCO.2021.39.15_suppl.7500

Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia. News release. AstraZeneca. January 25, 2021. Accessed June 9, 2021. https://bit.ly/2SjSPI4

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content